Antiphospholipid antibodies and antiphospholipid syndrome

Area of Science:

• Immunology
• Hematology
• Pathology

Background:

• Antiphospholipid syndrome (APS) is a significant autoimmune disorder characterized by recurrent thrombosis.
• Thrombosis in APS affects various vessel sizes and presents histopathologically as bland thrombi without inflammation.
• Over a decade since its detailed description, research continues to elucidate APS pathogenesis and clinical manifestations.

Purpose of the Study:

• To review current understanding of antiphospholipid syndrome (APS) pathophysiology and clinical aspects.
• To highlight new findings on the role of beta 2-glycoprotein I (β2GPI) in APS.
• To provide updated treatment recommendations for APS-associated thrombosis.

Main Methods:

• Review of recent clinical and experimental data on APS.
• Analysis of new biological insights into beta 2-glycoprotein I (β2GPI) function.
• Evaluation of histopathologic findings in APS-related thrombotic events.

Main Results:

• Animal models are yielding critical data on APS clinical and pathogenic features.
• Emerging evidence underscores the significance of beta 2-glycoprotein I (β2GPI) in APS pathogenesis.
• The presentation of phospholipid antigens is crucial, with β2GPI playing a key role.

Conclusions:

• Long-term anticoagulation therapy is essential for managing antiphospholipid syndrome (APS).
• Maintaining a high international normalized ratio (INR) is necessary to prevent recurrent thrombosis in APS.
• Further research into beta 2-glycoprotein I (β2GPI) is vital for understanding and treating APS.